Prospective, Randomized, Double-Blind Trial of Adjuvant Exisulind Versus Placebo for Patients at Risk for Prostate Cancer Recurrence After Radical Prostatectomy
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
Assess efficacy of drug vs placebo regarding overall rate of biochemical progression
Bradley C. Leibovich, M.D.
Principal Investigator
Mayo Clinic
United States: Food and Drug Administration
526-02
NCT00166426
February 2003
May 2008
Name | Location |
---|---|
Mayo Clinic | Rochester, Minnesota 55905 |